Literature DB >> 21309035

A SImplified method for Segregation Analysis (SISA) to determine penetrance and expression of a genetic variant in a family.

Pål Møller1, Neal Clark, Lovise Mæhle.   

Abstract

A method for SImplified rapid Segregation Analysis (SISA) to assess penetrance and expression of genetic variants in pedigrees of any complexity is presented. For this purpose the probability for recombination between the variant and the gene is zero. An assumption is that the variant of undetermined significance (VUS) is introduced into the family once only. If so, all family members in between two members demonstrated to carry a VUS, are obligate carriers. Probabilities for cosegregation of disease and VUS by chance, penetrance, and expression, may be calculated. SISA return values do not include person identifiers and need no explicit informed consent. There will be no ethical complications in submitting SISA return values to central databases. Values for several families may be combined. Values for a family may be updated by the contributor. SISA is used to consider penetrance whenever sequencing demonstrates a VUS in the known cancer-predisposing genes. Any family structure at hand in a genetic clinic may be used. One may include an extended lineage in a family through demonstrating the same VUS in a distant relative, and thereby identifying all obligate carriers in between. Such extension is a way to escape the selection biases through expanding the families outside the clusters used to select the families.
© 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21309035     DOI: 10.1002/humu.21441

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  6 in total

1.  Gene expression profile of peripheral blood in colorectal cancer.

Authors:  Yu-Tien Chang; Chi-Shuan Huang; Chung-Tay Yao; Sui-Lung Su; Harn-Jing Terng; Hsiu-Ling Chou; Yu-Ching Chou; Kang-Hua Chen; Yun-Wen Shih; Chian-Yu Lu; Ching-Huang Lai; Chen-En Jian; Chiao-Huang Lin; Chien-Ting Chen; Yi-Syuan Wu; Ke-Shin Lin; Thomas Wetter; Chi-Wen Chang; Chi-Ming Chu
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

2.  How does re-classification of variants of unknown significance (VUS) impact the management of patients at risk for hereditary breast cancer?

Authors:  Ava Kwong; Cecilia Yuen Sze Ho; Vivian Yvonne Shin; Chun Hang Au; Tsun-Leung Chan; Edmond Shiu Kwan Ma
Journal:  BMC Med Genomics       Date:  2022-05-31       Impact factor: 3.622

3.  Pure adult-onset spastic paraplegia caused by a novel mutation in the KIAA0196 (SPG8) gene.

Authors:  Susanne T de Bot; Sascha Vermeer; Wendy Buijsman; Angelien Heister; Marsha Voorendt; Aad Verrips; Hans Scheffer; Hubertus P H Kremer; Bart P C van de Warrenburg; Erik-Jan Kamsteeg
Journal:  J Neurol       Date:  2013-03-02       Impact factor: 4.849

4.  Assessing the pathogenicity of RYR1 variants in malignant hyperthermia.

Authors:  A Merritt; P Booms; M-A Shaw; D M Miller; C Daly; J G Bilmen; K M Stowell; P D Allen; D S Steele; P M Hopkins
Journal:  Br J Anaesth       Date:  2017-04-01       Impact factor: 9.166

5.  The Norwegian PMS2 founder mutation c.989-1G > T shows high penetrance of microsatellite instable cancers with normal immunohistochemistry.

Authors:  Eli Marie Grindedal; Harald Aarset; Inga Bjørnevoll; Elin Røyset; Lovise Mæhle; Astrid Stormorken; Cecilie Heramb; Heidi Medvik; Pål Møller; Wenche Sjursen
Journal:  Hered Cancer Clin Pract       Date:  2014-04-21       Impact factor: 2.857

Review 6.  Twenty Years of Ferroportin Disease: A Review or An Update of Published Clinical, Biochemical, Molecular, and Functional Features.

Authors:  L Tom Vlasveld; Roel Janssen; Edouard Bardou-Jacquet; Hanka Venselaar; Houda Hamdi-Roze; Hal Drakesmith; Dorine W Swinkels
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.